• Jeffrey A Allen, Deborah F Gelinas, Miriam Freimer, M Chris Runken, and Gil I Wolfe.
• Department of Neurology, Division of Neuromuscular Medicine, University of Minnesota, 516 Delaware Street SE, 12-150 PWB, Minneapolis, MN 55455, United States of America. Electronic address: jaallen@umn.edu.
• J. Neurol. Sci. 2020 Jan 15; 408: 116497.

AbstractChronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired neurological disorder characterized clinically by weakness and impaired sensory function evolving over 2 months or more, loss or significant decrease in deep tendon reflexes, and by electrophysiological evidence of peripheral nerve demyelination. Expeditious diagnosis and treatment of CIDP early in the disease course is critical such that irreversible disability can be avoided. Intravenous immunoglobulin (IVIG) is one first-line and maintenance therapy option for CIDP. The US Food & Drug Administration's (FDA's) approval of subcutaneous immunoglobulin (SCIG) in 2018 provides patients with CIDP more treatment options for maintenance therapy. The different options for administration of IG treatment create the need for information to assist clinicians and patients in choosing the optimal therapeutic approach. Considerations for pharmacokinetics, administration procedures, adverse events, patient variables, and cost will all be discussed in this article.Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

19 keywords...

hide…